Search Results

Site Search

NGS for Myeloid Neoplasm Evaluation - Insights

Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights

(Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance...

Urinary Steroid Profile Assay

Understanding the difference between benign and malignant adrenal tumors has alway been difficult; this new assay will assist with this medical challenge....

Infliximab Test Now Validated for Inflectra - Insights

of its existing Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum test for the new biosimilar...

Understanding Membranoproliferative Glomerulonephritis, Including C3 Glomerulopathy: Part 2 - Insights

Fervenza proposed a new histologic classification of MPGN into Ig/IC-mediated MPGN and complement-mediated MPGN. In this “Hot Topic,” Senjeev Sethi, M.D., Ph.D., demonstrates the use of the new classification...

Understanding Membranoproliferative Glomerulonephritis, Including C3 Glomerulopathy: Part 1 - Insights

Fervenza proposed a new histologic classification of MPGN into Ig/IC-mediated MPGN and complement-mediated MPGN. In this “Hot Topic,” Senjeev Sethi, M.D., Ph.D., demonstrates the use of the new classification...

Jane Hermansen, MT(ASCP), Discusses Potential Impact of Price Transparency Regulations - Insights

Jane Hermansen, MT(ASCP), was recently featured in 360Dx discussing new federal regulations aimed at hospital price transparency....

Groundbreaking collaborations - Insights

biopharma companies, and healthcare organizations around the globe, we are clearing the path for new technologies that will improve patient care....

Therapeutics events - Insights

TherapeuticS Creating the new standard of therapeutic management, together Mayo Clinic Laboratories’ evidence-based toxicology and pharmacogenomic testing...

Neurofilament Light Chain (NFLC) - Insights

describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s...